15 January 2026
The new lens will be introduced to the market in the same power range as CooperVision’s original MiSight 1-Day contact lens, and with the same parameters as the MyDay lens portfolio. It will also be released at the same cost as MiSight 1 day, CooperVision confirmed.
Speaking at an online introduction event in December, company representatives in professional affairs and marketing Lucy Davies, Chithra Dhanabalan, and Nicky Latham, highlighted the scale of adoption of myopia management across the UK and Ireland. They introduced the new lens as a next-generation myopia management daily disposable contact lens, combining proven myopia control technology with a silicone hydrogel material to support both clinical outcomes and patient experience.
Since launching the first myopia management contact lens to market in the UK and Ireland in 2020 with MiSight 1 day, the lens has been fitted and worn by more than 40,000 children, Davies reported.
Davies highlighted: “Myopia management in the UK is gaining significant momentum, with growing awareness among eye care professionals (ECPs), parents, and patients alike.”
She also noted that one in two children born today will have myopia by the age of 20, adding: “It is our duty as innovators, and you as ECPs, to recommend a myopia management option that you believe is relevant, to all myopic children.”
Davies said on the introduction of MyDay MySight 1 day,“this is about bringing our myopia management lens into our silicone hydrogel technology from the MyDay family – it’s an exciting new concept.”
Vision correction and contact lenses
Discussing myopia management intervention, Dhanabalan highlighted the importance of recommending the right intervention for each patient, noting that lifestyle and age may play a role in practitioner decision-making. She also emphasised the need to optimise compliance by educating both parents and children about optimal wear time.
Referring to a paper entitled Myopia control: seeing beyond efficacy by Mark Bullimore, Dhanabalan explained that Bullimore recommends ECPs consider four key parameters when selecting the most appropriate myopia management intervention: compliance, quality of vision, quality of life and safety.
She stressed that when asked by a parent or a colleague which myopia management modality is most effective, the answer should only be, the one the child will use.
For many children, the benefits of contact lenses and myopia management can be significant, with positive impacts on confidence, comfort, lifestyle and future career opportunities.
One case study shared with practitioners featured Dan, who participated in CooperVision’s early myopia management trial and is now serving in the military.
“When I went through the medical process for joining the military, I understood how close my eyesight was to the requirement, even with myopia control,” he said.
His mother, Donna, echoed the sentiment: “As a parent, you want the best for your child, and I think had Dan not been on that myopia management trial, I don’t know whether or not he’d be in the army today, following his dream.”
Why the new lens matters
Dhanabalan described MyDay MySight 1 day as “the next generation myopia management contact lens – a contact lens that provides performance today while helping children to achieve their potential in the future.”
Giving delegates a closer look at the new innovation, Dhanabalan explained that the lens uses “the ActivControl technology, which we know is proven to slow the worsening of myopia management in children. Then, because this lens uses MyDay material, we can benefit from AquaForm technology, which gives us high oxygen transmissibility and a naturally high wettable material for a comfortable and flexible lens.”
CooperVision confirmed that MyDay MySight 1-Day will deliver the same level of myopic defocus as the original MiSight 1 day lens, while offering up to four times the oxygen transmissibility. The lens also includes a UV blocker and uses a naturally wettable material designed to support comfort and flexibility, the company highlighted.
CooperVision reported that clinical evaluations found excellent vision, high comfort ratings, easy handling.
Davies confirmed that by introducing the lens in the same parameters as MyDay lenses, patients who no longer require myopia management can be comfortably transitioned into the MyDay lens portfolio.
“This is really exciting for us as a company,” Davies concluded. “We have got now a lens that you can confidently fit and take people and evolve them through as they go into a lifetime of wear in contact lenses.”
MyDay MySight 1 day will be available on the market from 19 January.
Trial lenses for MiSight 1-Day will stop in July this year, although the product itself will remain available, CooperVision confirmed.
Comments (0)
You must be logged in to join the discussion. Log in